Nevada PEBP

Q4 FY2026

Prepared by Client Analytics

Mathew Gehrin (mgehrin@express-scripts.com)

8/31/2026

**The data contained herein is pulled from a specific point-in-time and is subject to change at any time without notice due to a variety of factors, including but not limited to changes related to Member behavior, population demographics, system updates, and product availability. The data does not represent a guarantee and should not be used for audit purposes.*

Confidential Information

Hello PEBP Team,

This is the Q4 FY26 Summary File for the three State of Nevada PEBP plans (CDHP, EPO, and PPO). The summary contains Trend breakouts for each plan (Utilization, Unit Cost, and Cost Share). Along with the most notable changes of drugs within the top moving indications. Each plan breakout has a peer comparison of Trend. The file concludes with several Key Statistics of the three plans in aggregate.

CDHP Overall Trend Summaries:

CDHP Overall Trend		% Change
Current Period - Plan Cost Net PMPM	**$100.72**	
Utilization	$0.89	1.1%
Unit Cost	$12.58	15.4%
Member Share	$5.39	6.6%
Total Change in Plan Cost Net PMPM	**$18.86**	**23.0%**
Previous Period - Plan Cost Net PMPM	**$81.85**	

Top moving indications and most notable drug changes within the indications are as follows:

- **Inflammatory Conditions**: Previous ranked 2nd, currently ranked 1st by Plan Cost Net.
  - Plan Cost Net ↑ $1.24M (37.1%) to current $4.58M.
  - Plan Cost Net PMPM ↑ $4.98 (41.1%) to current $17.08.
  - Patient Count ↑ 18 to current count of 279.
  - Adjusted Rxs ↑ 132 to current count of 2,537.

- **Notable Drug Changes within Indication:**
  - **Ilaris:**
    - Previously ranked 28th , currently ranked 2nd by Plan Cost Net.
    - Plan Cost Net ↑ $476k (3,362.4%) to current $490k Plan Cost Net.
    - Plan Cost Net PMPM: ↑ $1.78 (3,464.5%) to current $1.83.
    - Patient Count ↑ 4 to current count of 5.
    - Adjusted Rxs ↑ 37 to current count of 38.
  - **Rinvoq:**
    - Previously ranked 2nd, currently ranked 1st by Plan Cost Net.
    - Plan Cost Net ↑ $136k (37.1%) to current $503k.
    - Plan Cost Net PMPM ↑ $.55 (41.2%) to current $1.88.
    - Patient Count ↑ 4 to current count of 17.
    - Adjusted Rxs ↑ 26 to current count of 135.
  - **Cosentyx Unoready Pen:**
    - New, currently ranked 7th by Plan Cost Net.
    - Plan Cost Net New, currently $190k.

        - Plan Cost Net PMPM New, currently $0.71.
        - Patient Count New, current count of 5.
        - Adjusted Rxs New, current count of 34.

- **Blood Cell Deficiencies**: Previously ranked 13th, currently ranked 46th by Plan Cost Net.
    - Plan Cost Net ↓ $355k (-91%) to current $34k.
    - Plan Cost Net PMPM ↓ $1.28 (-91.1%) to current $0.12.
    - Patient Count ↓ 15 to current count of 6.
    - Adjusted Rxs ↓ 8 to current count of 29.

- **Notable Drug Changes within Indication:**
    - **Promacta:**
        - No Longer Utilized, previously ranked 1st by Plan Cost Net.
        - Plan Cost Net: Previously $358k.
        - Plan Cost Net PMPM: Previously $1.33.
        - Patient Count: Previously 1.
        - Adjusted Rxs: Previously 10.
    - **Other drug changes in this indication were not notable.**

- **Pulmonary Hypertension**: Previously ranked 12th, currently ranked 7th by Plan Cost Net.
    - Plan Cost Net ↑ $923k (233.3%) to current $1.32M.
    - Plan Cost Net PMPM ↑ $3.48 (243.1%) to current $4.92.
    - Patient Count ↑ 3 to current count of 7.
    - Adjusted Rxs ↑ 71 to current count of 122.

- **Notable Drug Changes within Indication:**
    - **Tyvaso DPI:**
        - New, currently ranked 1st by Plan Cost Net.
        - Plan Cost Net: New, current $564k.
        - Plan Cost Net PMPM: New, current $2.10.
        - Patient Count: New, current count of 2.
        - Adjusted Rxs: New, current count of 26.
    - **Opsynvi:**
        - Previously ranked 3rd, currently ranked 3rd by Plan Cost Net
        - Plan Cost Net ↑ $173k (543.8%) to current $205k.
        - Plan Cost Net PMPM ↑ $0.65 (562.7%) to current $0.77.
        - Patient Count ↑ 1 to current count of 2.
        - Adjusted Rxs ↑ 21 to current count of 24.
    - **Winrevair:**
        - New, currently ranked 4th by Plan Cost Net.
        - Plan Cost Net: New, current $150k.
        - Plan Cost Net PMPM: New, current $0.56.
        - Patient Count: New, current count of 2.
        - Adjusted Rxs: New, current count of 10.

- **Cancer**: Previous ranked 1st , currently ranked 2nd by Plan Cost Net.
  - Plan Cost Net ↑ $686k (19.4%) to current $4.22M.
  - Plan Cost Net PMPM ↑ $2.93 (22.9%) to current $15.72.
  - Patient Count ↓ 7 to current count of 228.
  - Adjusted Rxs ↓ 99 to current count of 1,639.

- **Notable Drug Changes within Indication:**
  - **Verzenio**
    - Previously ranked 7th, currently ranked 1st by Plan Cost Net
    - Plan Cost Net ↑ $226k (100.2%) to current $451k.
    - Plan Cost Net PMPM ↑ $0.87 (106.1%) to current $1.68.
    - Patient Count ↑ 1 to current count of 4.
    - Adjusted Rxs ↑ 15 to current count of 34.
  - **Kisqali**
    - New, currently ranked 10th by Plan Cost Net.
    - Plan Cost Net: New, current $195k.
    - Plan Cost Net PMPM: New, current $0.73.
    - Patient Count: New, current count of 2.
    - Adjusted Rxs: New, current count of 16.
  - **Tagrisso**
    - Previously ranked 3rd, currently ranked 2nd by Plan Cost Net
    - Plan Cost Net ↑ $141k (47.9%) to current $436k.
    - Plan Cost Net PMPM ↑ $0.56 (52.2%) to current $1.63.
    - Patient Count unchanged at 2.
    - Adjusted Rxs ↑ 9 to current count of 26.

- **Enzyme Deficiencies**: Previously ranked 42nd, currently ranked 13th by Plan Cost Net.
  - Plan Cost Net ↑ $380k (1,209.7%) to current $576k.
  - Plan Cost Net PMPM ↑ $1.99 (1,248.3%) to current $2.15.
  - Patient Count ↑ 4 to current count of 6.
  - Adjusted Rxs ↑ 17 to current count of 25.

- **Notable Drug Changes within Indication:**
  - **Fabrazyme:**
    - New, currently ranked 1st by Plan Cost Net.
    - Plan Cost Net: New, current $463k.
    - Plan Cost Net PMPM: New, current $1.73.
    - Patient Count: New, current count of 1.
    - Adjusted Rxs: New, current count of 12.
  - **Other drug changes in this indication were not notable.**

Peer Comparison:

- Peer: ESI CDH Program
- PEBP CDHP is outperforming the peer in Plan Cost Net PMPM but has a higher trend.

- Peer experienced Plan Cost Net PMPM of $109.57 compared to CDHP PEBP of $100.72.
- Peer experienced Trend of 15.2%, compared to CDHP PEBP Trend of 23.0%

EPO Overall Trend Summaries:

EPO Overall Trend		% Change
Current Period - Plan Cost Net PMPM	**$214.63**	
Utilization	$9.66	5.3%
Unit Cost	$11.63	6.4%
Member Share	$11.06	6.1%
Total Change in Plan Cost Net PMPM	**$32.35**	**17.8%**
Previous Period - Plan Cost Net PMPM	**$182.27**	

Top moving indications and most notable drug changes within the indications are as follows:

- **Blood Cell Deficiencies**: Previous ranked 9th, currently ranked 46th by Plan Cost Net.
  - Plan Cost Net ↓ $363k (-97.4%) to current $10k.
  - Plan Cost Net PMPM ↓ $5.82 (-97.0%) to current $0.18.
  - Patient Count ↓ 3 to current count of 1.
  - Adjusted Rxs ↓ 0 to current count of 18.

- **Notable Drug Changes within Indication:**
  - **Cablivi:**
    - Previously ranked 1st, not currently utilized.
    - Plan Cost Net: Previous, $359k.
    - Plan Cost Net PMPM: Previous, $5.77.
    - Patient Count: Previous count of 1.
    - Adjusted Rxs: Previous count of 2.
  - **Other drug changes in this indication were not notable.**

- **Diabetes**: Previously ranked 2nd, currently ranked 2nd by Plan Cost Net.
  - Plan Cost Net ↑ $183k (-13.2%) to current $1.6M.
  - Plan Cost Net PMPM ↑ $7.15 (32.0%) to current $29.50.
  - Patient Count ↓ 66 to current count of 559.
  - Adjusted Rxs ↓ 1,086 to current count of 9,973.

- **Notable Drug Changes within Indication:**
  - **Mounjaro:**
    - Previously ranked 2nd, currently ranked 1st by Plan Cost Net.
    - Plan Cost Net ↑ $254k (66.1%) to current $639k.
    - Plan Cost Net PMPM ↑ $5.81 (93.7%) to current $12.01.

        - Patient Count ↑ 58 to current count of 184.
        - Adjusted Rxs ↑ 482 to current count of 1,585.
    - **Other drug changes in this indication were not notable.**

- **Muscle Relaxant**: Previously ranked 60th, currently ranked 14th by Plan Cost Net.
    - Plan Cost Net ↑ $222k (4,520.7%) to current $227k.
    - Plan Cost Net PMPM ↑ $4.18 (5,289.9%) to current $4.26.
    - Patient Count ↓ 8 to current count of 470.
    - Adjusted Rxs ↓ 4 to current count of 1,865.

- **Notable Drug Changes within Indication:**
    - **Skyclarys:**
        - New, Currently ranked 1st by Plan Cost Net.
        - Plan Cost Net: New, current $223k.
        - Plan Cost Net PMPM: New, current $4.18.
        - Patient Count: New, current count of 1.
        - Adjusted Rxs: New, current count of 7.
    - **Other drug changes in this indication were not notable.**

- **Endocrine Disorders**: Previously ranked 13th, currently ranked 23rd by Plan Cost Net.
    - Plan Cost Net ↓ $119k (-48.5%) to current $126k.
    - Plan Cost Net PMPM ↓ $1.57 (-39.9%) to current $2.37.
    - Patient Count ↓ 7 to current count of 27.
    - Adjusted Rxs ↓ 46 to current count of 185.

- **Notable Drug Changes within Indication:**
    - **Korlym:**
        - No Longer utilized, previously ranked 2nd by Plan Cost Net.
        - Plan Cost Net: Previously $81k.
        - Plan Cost Net PMPM: Previously $1.29
        - Patient Count: Previous count of 2.
        - Adjusted Rxs: Previous count of 2.
    - **Supprelin LA:**
        - No Longer utilized, previously ranked 3rd by Plan Cost Net.
        - Plan Cost Net: Previously $49k.
        - Plan Cost Net PMPM: Previously $0.78.
        - Patient Count: Previous count of 1.
        - Adjusted Rxs: Previous count of 12.
    - **Other drug changes in this indication were not notable.**

Peer Comparison:

- Government – West Region/SaveOn (custom peer created for PEBP EPO plan)
- The peer is outperforming PEBP EPO in Plan Cost Net PMPM, however PEBP EPO plan has a lower trend.
- Peer experienced Plan Cost Net PMPM of $173.48 compared to PEBP EPO of $214.63

- Peer experienced Trend of 19.7%, compared to PEBP EPO of 17.8%

PPO Overall Trend Summaries:

PPO Overall Trend		% Change
Current Period - Plan Cost Net PMPM	**$134.73**	
Utilization	$6.19	5.8%
Unit Cost	$15.43	14.4%
Member Share	$6.16	5.8%
Total Change in Plan Cost Net PMPM	**$27.79**	**26.0%**
Previous Period - Plan Cost Net PMPM	**$106.94**	

Top moving indications and most notable drug changes within the indications are as follows:

- **Inflammatory Conditions**: Previously ranked 1st, currently ranked 1st by Plan Cost Net.
  - Plan Cost Net ↑ $2.5M (57.6%) to current $6.8M.
  - Plan Cost Net PMPM ↑ $6.72 (43.8%) to current $22.07.
  - Patient Count ↑ 80 to current count of 443.
  - Adjusted Rxs ↑ 686 to current count of 3,950.

- **Notable Drug Changes within Indication:**
  - **Rinvoq:**
    - Previously ranked 1st, currently ranked 1st by Plan Cost Net.
    - Plan Cost Net ↑ $301k (52.0%) to current $880k.
    - Plan Cost Net PMPM ↑ $0.80 (38.7%) to current $2.86.
    - Patient Count ↑ 6 to current count of 27.
    - Adjusted Rxs ↑ 58 to current count of 232.
  - **Bimzelx Autoinjector:**
    - Previously ranked 17th, currently ranked 4th by Plan Cost Net.
    - Plan Cost Net ↑ $293k (455.0%) to current $358k.
    - Plan Cost Net PMPM ↑ $0.93 (406.4%) to current $1.16.
    - Patient Count ↑ 7 to current count of 9.
    - Adjusted Rxs ↑ 35 to current count of 58.
  - **Adalimumab-ADBM(CF) Pen (Humira Biosimilar):**
    - Previously ranked 50th, currently ranked 6th by Plan Cost Net.
    - Plan Cost Net ↑ $281k (9,809.8%) to current $284k.
    - Plan Cost Net PMPM ↑ $0.91 (8,942.1%) to current $0.92.
    - Patient Count ↑ 37 to current count of 40.
    - Adjusted Rxs ↑ 258 to current count of 261.
  - **Stelara:**
    - Previously ranked 3rd, currently ranked 10th by Plan Cost Net.
    - Plan Cost Net ↓ $239k (-51.5%) to current $225k.
    - Plan Cost Net PMPM ↓ $0.92 (-55.8%) to current $0.73.
    - Patient Count ↓ 1 to current count of 13.
    - Adjusted Rxs ↓ 38 to current count of 107.

- **Enzyme Deficiencies**: Previously ranked 5th, currently ranked 5th by Plan Cost Net.
  - Plan Cost Net ↑ $1.1M (75.6%) to current $2.6M.
  - Plan Cost Net PMPM ↑ $3.20 (60.2%) to current $8.52.
  - Patient Count ↓ 1 to current count of 11.
  - Adjusted Rxs ↑ 54 to current count of 112.

- **Notable Drug Changes within Indication:**
  - **Yorvipath:**
    - Previously ranked 2nd, currently ranked 1st by Plan Cost Net.
    - Plan Cost Net ↑ $1.1M (555.6%) to current $1.3M.
    - Plan Cost Net PMPM ↑ $3.54 (498.2%) to current $4.25.
    - Patient Count ↑ 4 to current count of 6.
    - Adjusted Rxs ↑ 55 to current count of 64.
  - **Imcivree:**
    - Previously ranked 7th, currently ranked 3rd by Plan Cost Net.
    - Plan Cost Net ↑ $311k (293.9%) to current $416k.
    - Plan Cost Net PMPM ↑ $0.98 (259.4%) to current $1.35.
    - Patient Count ↑ 1 to current count of 2.
    - Adjusted Rxs ↑ 11 to current count of 15.

- **Diabetes**: Previously ranked 2nd, currently ranked 2nd by Plan Cost Net.
  - Plan Cost Net ↑ $1.2M (30.8%) to current $5.2M.
  - Plan Cost Net PMPM ↑ $2.71 (19.3%) to current $16.72.
  - Patient Count ↑ 188 to current count of 2,235.
  - Adjusted Rxs ↑ 2,350 to current count of 33,383.

- **Notable Drug Changes within Indication:**

  - **Mounjaro:**
    - Previously ranked 1st, currently ranked 1st by Plan Cost Net.
    - Plan Cost Net ↑ $1.0M (72.3%) to current $2.4M.
    - Plan Cost Net PMPM ↑ $2.85 (57.2%) to current $7.82.
    - Patient Count ↑ 229 to current count of 693.
    - Adjusted Rxs ↑ 2,259 to current count of 6,352.

  - **Other drug changes in this indication were not notable.**

- **Atopic Dermatitis**: Previously ranked 6th, currently ranked 6th by Plan Cost Net.
  - Plan Cost Net ↑ $837k (62.5%) to current $2.2M.
  - Plan Cost Net PMPM ↑ $2.30 (48.3%) to current $7.06.
  - Patient Count ↑ 186 to current count of 2,060.
  - Adjusted Rxs ↑ 594 to current count of 4,328.

- **Notable Drug Changes within Indication:**

- **Dupixent Pen:**
  - Previously ranked 1st, currently ranked 1st by Plan Cost Net.
  - Plan Cost Net ↑ $506k (55.3%) to current $1.4M.
  - Plan Cost Net PMPM ↑ $1.36 (41.7%) to current $4.61.
  - Patient Count ↑ 11 to current count of 74.
  - Adjusted Rxs ↑ 133 to current count of 631.

- **Dupixent Syringe:**
  - Previously ranked 2nd, currently ranked 2nd by Plan Cost Net.
  - Plan Cost Net ↑ $124k (65.5%) to current $314k.
  - Plan Cost Net PMPM ↑ $0.34 (51.1%) to current $1.02.
  - Patient Count ↑ 4 to current count of 21.
  - Adjusted Rxs ↑ 30 to current count of 128.

Peer Comparison:

- Government – West Region/SaveOn (custom peer created for PEBP PPO plan)
- PEBP PPO is outperforming the peer in Plan Cost Net PMPM, however PEBP PPO plan has a slightly higher trend.
- PEBP PPO experienced Plan Cost Net PMPM of $134.73 compared to peer of $173.48.
- Peer experienced Trend of 19.7%, compared to PEBP PPO of 26.0%.

Total Overall Trend		% Change
Current Period - Plan Cost Net PMPM	**$127.01**	
Utilization	$3.14	3.0%
Unit Cost	$14.03	13.6%
Member Share	$6.53	6.3%
Total Change in Plan Cost Net PMPM	**$23.70**	**22.9%**
Previous Period - Plan Cost Net PMPM	**$103.32**	

Summary of Total – Overall the main driver of Trend was Specialty Utilization driven by an increase of 19.6% in Specialty patients. This resulted in a 21.1% increase in Specialty Days of Therapy, the majority of which are single source brands.

Trend was mitigated by increased rebates of 4.8%. Which reduced combine Unit Cost Trend to 13.6%.

Member Cost contributed to Trend on both Specialty and Non-Specialty drugs. This is due to increased Utilization on Specialty drugs and the utilization of more expensive Non-Specialty brand drugs (exchanging utilization of a brand drug for a more expensive brand drug) which drives Drug Mix and reduces member contributions as a percent of overall costs.

Key Statistics:

Nevada PEBP Total			
Description	Q4 FY26	Q4 FY25	Change
Average Members per Month	52,462	51,616	1.6%
Number of Unique patients	40,267	39,485	2.0%
Members Utilizing the Benefit	76.8%	76.5%	0.3
Gross Cost/Adjusted Rx	$165.77	$150.88	9.9%
Plan Spend	$119,875,724	$102,090,425	17.4%
Rebates (estimated)	$39,914,437	$38,095,754	4.8%
Plan Cost Net	$79,961,287	$63,994,671	24.9%
Plan Cost Net PMPM	$127.01	$103.32	22.9%
Non-Specialty Plan Cost Net PMPM	$85.79	$80.73	6.3%
Specialty Plan Cost Net PMPM	$104.63	$84.09	24.4%
Generic Fill Rate	87.3%	87.1%	0.1
90 Day Utilization	59.6%	59.9%	-0.3
Retail - Maintenance 90 Utilization	32.2%	29.5%	2.7
Home Delivery Utilization	25.8%	29.2%	-3.4
Member Cost Net %	14.8%	17.1%	-2.3

END OF REPORT